$29.80 Million in Sales Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter

Wall Street analysts expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to post sales of $29.80 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings, with estimates ranging from $21.66 million to $37.09 million. Lexicon Pharmaceuticals reported sales of $23.04 million in the same quarter last year, which suggests a positive year over year growth rate of 29.3%. The business is expected to issue its next quarterly earnings results on Friday, March 2nd.

According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full year sales of $29.80 million for the current financial year, with estimates ranging from $78.94 million to $94.37 million. For the next year, analysts forecast that the business will post sales of $122.05 million per share, with estimates ranging from $110.64 million to $129.40 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Lexicon Pharmaceuticals.

LXRX has been the topic of several recent research reports. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. Wedbush reissued an “outperform” rating and issued a $38.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Thursday, November 30th. ValuEngine cut shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Finally, BidaskClub raised shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 20th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $28.50.

In related news, CEO Lonnel Coats purchased 10,000 shares of the stock in a transaction dated Wednesday, November 15th. The shares were acquired at an average cost of $9.91 per share, with a total value of $99,100.00. Following the purchase, the chief executive officer now directly owns 42,985 shares in the company, valued at approximately $425,981.35. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Public Equities L.P. Invus purchased 180,727 shares of the stock in a transaction dated Friday, November 17th. The shares were bought at an average cost of $10.11 per share, for a total transaction of $1,827,149.97. The disclosure for this purchase can be found here. Corporate insiders own 5.77% of the company’s stock.

Large investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth $182,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth $117,000. Cubist Systematic Strategies LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter worth $149,000. Aperio Group LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter worth about $127,000. Finally, C WorldWide Group Holding A S boosted its position in shares of Lexicon Pharmaceuticals by 49.6% in the 3rd quarter. C WorldWide Group Holding A S now owns 16,146 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 5,353 shares in the last quarter.

Lexicon Pharmaceuticals (NASDAQ LXRX) opened at $9.24 on Tuesday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.66 and a quick ratio of 1.65. The stock has a market cap of $980.91, a price-to-earnings ratio of -7.33 and a beta of 0.24. Lexicon Pharmaceuticals has a 12 month low of $8.07 and a 12 month high of $18.00.

TRADEMARK VIOLATION WARNING: “$29.80 Million in Sales Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter” was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/02/13/29-80-million-in-sales-expected-for-lexicon-pharmaceuticals-inc-lxrx-this-quarter.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply